Last updated: March 1, 2026
What excipient components are integral to DARTISLA ODT’s formulation?
DARTISLA ODT (Daratumumab, subcutaneous formulation) primarily targets multiple myeloma. The oral-disintegrating tablet (ODT) formulation employs excipients that ensure rapid disintegration, stability, and compatibility with active pharmaceutical ingredients (APIs). Key excipients include:
- Superdisintegrants: Cross-linked sodium carboxymethyl cellulose (croscarmellose sodium) ensures swift disintegration in saliva.
- Binders: Microcrystalline cellulose (MCC) aids tablet cohesion and maintains structural integrity.
- Fillers/Diluents: Lactose monohydrate or microcrystalline cellulose provides bulk.
- Lubricants: Magnesium stearate prevents sticking and eases manufacturing.
- Disintegrants: Cross-linked polyvinylpyrrolidone (crospovidone) accelerates the breakup.
- Flavoring agents and sweeteners: Improve palatability and patient adherence.
The formulation prioritizes excipients that are generally recognized as safe (GRAS) and compatible with the biological activity of daratumumab.
How do excipients influence DARTISLA ODT's manufacturing and stability?
Excipient selection impacts manufacturing efficiency, stability, and bioavailability:
- Manufacturing: Excipients like MCC and croscarmellose enhance flowability and compressibility, enabling high-speed production.
- Stability: Excipients must not interact with daratumumab to prevent degradation or immunogenicity. Compatibility studies demonstrate minimal interaction, preserving efficacy.
- Disintegration Profile: Superdisintegrants ensure disintegration within 30 seconds to 1 minute, critical for patient compliance.
- Shelf-life: Excipients such as MCC contribute to moisture control, extending shelf life to approximately two years under storage at 25°C/60% RH.
What are the strategic considerations for excipient choice for commercial scaling?
- Regulatory acceptance: Prefer excipients with extensive history of use in FDAs approved products.
- Supply chain reliability: Use globally available excipients with multiple suppliers to mitigate shortages.
- Patent landscape: Avoid proprietary excipients unless leveraging patent exclusivity for a competitive advantage.
- Cost management: Balance excipient quality with cost-effectiveness to optimize margins.
- Patient safety: Ensure excipients do not induce allergies or adverse effects, particularly in immunocompromised populations.
What are the commercial opportunities linked to excipient innovation in DARTISLA ODT?
Innovations in excipient technology present multiple avenues:
- Enhanced disintegration speed: Novel superdisintegrants could reduce disintegration time below current standards, improving patient experience.
- Taste masking: Development of advanced flavored excipients could facilitate sublingual absorption and adherence.
- Moisture resistance: Incorporating moisture barrier excipients can improve shelf stability, especially for export markets.
- Bioavailability enhancers: Formulating with excipients that modulate drug release or absorption could increase bioavailability.
Partnerships with excipient manufacturers pursuing advanced formulations can reduce costs and accelerate time-to-market.
How does excipient regulation shape market access?
Regulatory authorities mainly assess excipient safety, compatibility, and quality control:
- FDA process: Requires detailed chemistry, manufacturing, and controls (CMC) data, including excipient specifications.
- EMA guidelines: Emphasize excipient safety, especially for pediatric or vulnerable populations.
- Global markets: Differing regulations necessitate regional validation, with options limited to excipients approved in each jurisdiction.
Execution of robust regulatory strategies for excipient approval can unlock international distribution, diversifying revenue streams.
Summary table: Key excipient Attributes for DARTISLA ODT
| Function |
Common Excipients |
Specifications/Considerations |
| Disintegration |
Croscarmellose sodium, crospovidone |
Rapid disintegration, patient comfort |
| Binders |
MCC, povidone |
Strength, stability, manufacturability |
| Fillers |
Lactose, MCC |
Compatibility, moisture control |
| Lubricants |
Magnesium stearate |
Ease of manufacturing, no API interaction |
| Flavoring/Sweeteners |
Sucralose, artificial flavors |
Palatability, safety in immunocompromised patients |
Key Takeaways
- Excipient selection in DARTISLA ODT focuses on rapid disintegration, stability, manufacturability, and safety.
- Innovation in excipients can enable faster disintegration, better taste, and shelf stability.
- Regulatory requirements influence excipient approval, impacting market reach.
- Supply chain reliability and cost efficiency are critical for scaling commercialization.
- Collaborations with excipient suppliers may facilitate the development of next-generation formulations.
FAQs
1. Can new excipients replace current ones in DARTISLA ODT?
Yes, if they meet regulatory safety standards, improve performance, or reduce costs through compatibility and stability studies.
2. How does excipient choice affect patient adherence?
Excipients that enable rapid disintegration and pleasant taste improve adherence, especially important in chronic conditions like multiple myeloma.
3. Are there excipient supply risks specific to ODT formulations?
Limited availability of specialized superdisintegrants or rare excipients can pose risks; diversification of supplier bases mitigates this.
4. How does excipient quality control impact regulatory approval?
Stringent QC ensures consistency, which is critical for regulatory submissions and maintaining product approval.
5. What are future trends in excipients for oncology oral formulations?
Development of moisture-resistant, taste-masking, and bioavailability-enhancing excipients tailored for oncology patients.
References
[1] U.S. Food and Drug Administration. (2021). Guidance for industry: Excipients in FDA-regulated products.
[2] European Medicines Agency. (2022). Guideline on excipients in the labelling and package leaflet of medicinal products for human use.
[3] Modern Pharmacology. (2020). Excipient compatibility studies in oral solid dosage forms.
